Ihsan Kaplan
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Ihsan Kaplan has a total of 66 co-authors. Here are the top co-authors by number of shared publications:
Canan Can
Department of Nuclear Medicine, Saglik Bilimleri University
8 shared publicationsYunus Güzel
Department of Nuclear Medicine, Saglik Bilimleri University
7 shared publications- Yunus Güzel
Department of Nuclear Medicine, University of Health Sciences, Gazi Yasargil Training and Research Hospital, Diyarbakır, Turkey
7 shared publications Ferat Kepenek
Department of Nuclear Medicine, Saglik Bilimleri University
6 shared publicationsHalil Kömek
Department of Nuclear Medicine, Saglik Bilimleri University
6 shared publications- Halil Kömek
Department of Nuclear Medicine, Diyarbakır Gazi Yaşargil Training and Research Hospital, University of Health Sciences, Diyarbakır, Turkey;
6 shared publications
Latest Publications
- 11 December 2025
- Published by Elsevier in Clinical Genitourinary Cancer
- Vol. 24 (1) , 102482
Association of Fat and Muscle Mass With Overall Survival in Patients With Metastatic Prostate Cancer Treated With Enzalutamide, Abiraterone, and Docetaxel
- 11 December 2025
- Published by Elsevier in Clinical Genitourinary Cancer
- Vol. 24 (1) , 102482
Association of Fat and Muscle Mass With Overall Survival in Patients With Metastatic Prostate Cancer Treated With Enzalutamide, Abiraterone, and Docetaxel
- Open Access
- 30 July 2025
- Published by Journal of Health Sciences and Medicine in Journal of Health Sciences and Medicine
- Vol. 8 (4) , 720-725
Relationship between spleen volume, spleen/liver SUVmax ratio, and percentage change and overall survival in patients undergoing immunotherapy
Aims: This study aimed to investigate the pre- and post-treatment associations between spleen volume (SV), spleen/liver maximum standardized uptake value (SUVmax) ratio (SLR), and percent change (Δ) and overall survival (OS) in patients undergoing immunotherapy. Methods: This retrospective study included 89 patients who underwent 18F FDG PET/CT imaging before immunotherapy (baseline) and during post-treatment at 3 and 6 months. SV, spleen SUVmax, and liver SUVmax parameters were determined based on PET/CT images. Patients’ ages and date of mortality were recorded. Results: In the present study, 52 (58.4%) were men, and the median OS was 17.7 (4-83) months. Furthermore, 63 out of 89 patients (70.8%) died during the study period. Baseline median SV value was 230 ml (47-1870). Baseline median SLR value was 0.80 (0.33-1.48). Median ΔSV1 at baseline and at 3 months post-treatment was -1.34 (-55.03-155.37). Percent change in SLR baseline and post-treatment (ΔSLR1) median was -0.52 (-48.39-121.02). Moreover, SLR1 had a sensitivity of 64.2% and specificity of 65.2% in detecting mortality with a cutoff value of >0.80. For a SLR1 value of ≤0.79, median OS was 29.5 months and 1-3-year survival was 87/37%. SLR1 and SLR3 were independent prognostic factors for OS (p=0.003 and p=0.004, respectively). Conclusion: SV values before and at 3 months post-immunotherapy and SLR values before and at 6 months post-treatment were prognostic factors for OS. Higher SLR1 and SLR3 values from 18F FDG PET/CT before and at 6 months post-treatment were independent prognostic factors and associated with shorter OS.
- 30 July 2025
- Published by Journal of Health Sciences and Medicine in Journal of Health Sciences and Medicine
- Vol. 8 (4) , 720-725
Open AccessRelationship between spleen volume, spleen/liver SUVmax ratio, and percentage change and overall survival in patients undergoing immunotherapy
Aims: This study aimed to investigate the pre- and post-treatment associations between spleen volume (SV), spleen/liver maximum standardized uptake value (SUVmax) ratio (SLR), and percent change (Δ) and overall survival (OS) in patients undergoing immunotherapy. Methods: This retrospective study included 89 patients who underwent 18F FDG PET/CT imaging before immunotherapy (baseline) and during post-treatment at 3 and 6 months. SV, spleen SUVmax, and liver SUVmax parameters were determined based on PET/CT images. Patients’ ages and date of mortality were recorded. Results: In the present study, 52 (58.4%) were men, and the median OS was 17.7 (4-83) months. Furthermore, 63 out of 89 patients (70.8%) died during the study period. Baseline median SV value was 230 ml (47-1870). Baseline median SLR value was 0.80 (0.33-1.48). Median ΔSV1 at baseline and at 3 months post-treatment was -1.34 (-55.03-155.37). Percent change in SLR baseline and post-treatment (ΔSLR1) median was -0.52 (-48.39-121.02). Moreover, SLR1 had a sensitivity of 64.2% and specificity of 65.2% in detecting mortality with a cutoff value of >0.80. For a SLR1 value of ≤0.79, median OS was 29.5 months and 1-3-year survival was 87/37%. SLR1 and SLR3 were independent prognostic factors for OS (p=0.003 and p=0.004, respectively). Conclusion: SV values before and at 3 months post-immunotherapy and SLR values before and at 6 months post-treatment were prognostic factors for OS. Higher SLR1 and SLR3 values from 18F FDG PET/CT before and at 6 months post-treatment were independent prognostic factors and associated with shorter OS.
- Open Access
- 30 May 2025
- Published by Journal of Health Sciences and Medicine in Journal of Health Sciences and Medicine
- Vol. 8 (3) , 430-434
Prognostic importance of PET score obtained from IMPeTUS criteria in multiple myeloma
Aim Multiple myeloma (MM) is a clonal plasma cell malignancy that infiltrates the bone marrow, bone, and sometimes extramedullary sites. Reliable staging and prognostic factors are essential for patient management. Imaging modalities, especially [18F]FDG PET/CT, are essential for the assessment of disease extent. This study evaluates a scoring system based on the IMPeTUs criteria for predicting progression-free survival (PFS) in MM. Materials and Methods This study included 35 newly diagnosed, treatment-naive MM patients (13 females, 22 males). Baseline [18F]FDG PET/CT scans were obtained within one month of diagnosis. Data on MM type, ISS stage, chemotherapy regimens and outcomes were collected. PET/CT scans were evaluated using the IMPeTUs criteria, focusing on the Deauville 5-point scoring system for bone marrow and lesions. Results The mean age of the cohort was 65 years. Ig G kappa was the most common MM type (37.1%). Diffuse bone marrow uptake and focal lesions were observed in 37.2% and 57.2% of patients, respectively, DS ≥ 4. The PET score cut-off of 6.5 predicted PFS with 61.5% sensitivity and 72.7% specificity (AUC 0.715). Median PFS was significantly different between patients with PET score < 6.5 and ≥ 6.5 (35 ± 4.1 months vs. 23.6 ± 4.03 months, p = 0.027). Conclusions The PET score cut-off value of 6.5 serves as a potential prognostic tool for MM, aiding in patient stratification and treatment decisions.
- 30 May 2025
- Published by Journal of Health Sciences and Medicine in Journal of Health Sciences and Medicine
- Vol. 8 (3) , 430-434
Open AccessPrognostic importance of PET score obtained from IMPeTUS criteria in multiple myeloma
Aim Multiple myeloma (MM) is a clonal plasma cell malignancy that infiltrates the bone marrow, bone, and sometimes extramedullary sites. Reliable staging and prognostic factors are essential for patient management. Imaging modalities, especially [18F]FDG PET/CT, are essential for the assessment of disease extent. This study evaluates a scoring system based on the IMPeTUs criteria for predicting progression-free survival (PFS) in MM. Materials and Methods This study included 35 newly diagnosed, treatment-naive MM patients (13 females, 22 males). Baseline [18F]FDG PET/CT scans were obtained within one month of diagnosis. Data on MM type, ISS stage, chemotherapy regimens and outcomes were collected. PET/CT scans were evaluated using the IMPeTUs criteria, focusing on the Deauville 5-point scoring system for bone marrow and lesions. Results The mean age of the cohort was 65 years. Ig G kappa was the most common MM type (37.1%). Diffuse bone marrow uptake and focal lesions were observed in 37.2% and 57.2% of patients, respectively, DS ≥ 4. The PET score cut-off of 6.5 predicted PFS with 61.5% sensitivity and 72.7% specificity (AUC 0.715). Median PFS was significantly different between patients with PET score < 6.5 and ≥ 6.5 (35 ± 4.1 months vs. 23.6 ± 4.03 months, p = 0.027). Conclusions The PET score cut-off value of 6.5 serves as a potential prognostic tool for MM, aiding in patient stratification and treatment decisions.
- 6 May 2025
- Published by Wolters Kluwer Health in Nuclear Medicine Communications
- Vol. 46 (6) , 553-557
Contribution of tubarial salivary gland function detected through 68Ga-prostate-specific membrane antigen PET/computed tomography to total salivary gland function
Objective: This study aimed to determine the contribution of tubarial salivary glands to total salivary gland function using quantitative parameters obtained from 68Ga-prostate-specific membrane antigen (PSMA) PET/computed tomography (PET/CT), including salivary gland volume (SV) and salivary gland function (SF). Method: This retrospectively designed study included 102 patients with prostate cancer (PCa) who had undergone 68Ga-PSMA PET/CT for staging purposes between January 2022 and December 2023. Patients with missing data, those with tumors in the head and neck region, those who received radiotherapy to the head and neck region, those who underwent surgery in the head and neck region, those with any salivary gland-related disease, those previously treated with radioactive iodine, and those who received lutetium-177 (177Lu) therapy were excluded from the study. Results: All 102 patients included in the study were male and diagnosed with PCa. The mean age of the patients was calculated as 72.53 ± 7.58 years. Patients’ tubarial SV% and tubarial SF% values were calculated as 7.76 ± 4.01 and 2.58 ± 1.34, respectively. The percentage volume of tubarial glands was found to be statistically significantly higher than that of sublingual glands (P < 0.001, Wilcoxon signed-rank test). No statistical difference, however, was observed in their contributions to total function (P = 0.506). Conclusion: When examining the volume ratios of salivary glands showing PSMA expression, it was found that the tubarial salivary glands had a higher volumetric ratio but a lower contribution to total function. We recommend considering these ratios when administering treatments that affect salivary gland functions.
- 6 May 2025
- Published by Wolters Kluwer Health in Nuclear Medicine Communications
- Vol. 46 (6) , 553-557
Contribution of tubarial salivary gland function detected through 68Ga-prostate-specific membrane antigen PET/computed tomography to total salivary gland function
Objective: This study aimed to determine the contribution of tubarial salivary glands to total salivary gland function using quantitative parameters obtained from 68Ga-prostate-specific membrane antigen (PSMA) PET/computed tomography (PET/CT), including salivary gland volume (SV) and salivary gland function (SF). Method: This retrospectively designed study included 102 patients with prostate cancer (PCa) who had undergone 68Ga-PSMA PET/CT for staging purposes between January 2022 and December 2023. Patients with missing data, those with tumors in the head and neck region, those who received radiotherapy to the head and neck region, those who underwent surgery in the head and neck region, those with any salivary gland-related disease, those previously treated with radioactive iodine, and those who received lutetium-177 (177Lu) therapy were excluded from the study. Results: All 102 patients included in the study were male and diagnosed with PCa. The mean age of the patients was calculated as 72.53 ± 7.58 years. Patients’ tubarial SV% and tubarial SF% values were calculated as 7.76 ± 4.01 and 2.58 ± 1.34, respectively. The percentage volume of tubarial glands was found to be statistically significantly higher than that of sublingual glands (P < 0.001, Wilcoxon signed-rank test). No statistical difference, however, was observed in their contributions to total function (P = 0.506). Conclusion: When examining the volume ratios of salivary glands showing PSMA expression, it was found that the tubarial salivary glands had a higher volumetric ratio but a lower contribution to total function. We recommend considering these ratios when administering treatments that affect salivary gland functions.
- 1 May 2025
- Published by Wolters Kluwer Health in Nuclear Medicine Communications
- Vol. 46 (7) , 592-598
Effect of body composition parameters, including sarcopenia, myosteatosis, and adipose tissue, on overall survival of patients with mCRPC receiving 177Lu-PSMA PRRT
Purpose: This study aimed to examine the role of computed tomography (CT)-derived myosteatosis, sarcopenia, and other body composition parameters on overall survival (OS) in patients with metastatic castration-resistant prostate cancer (mCRPC) scheduled to receive lutetium (Lu)-177 treatment. Material and method: Patients with mCRPC who underwent 68 Ga-prostate-specific membrane antigen (PSMA) PET/CT imaging before [ 177 Lu]Lu-PSMA-617 treatment and received at least two cycles of Lu-177 PSMA treatment between March 2017 and March 2023 were retrospectively reviewed in this study. Body composition including psoas muscle, skeletal muscle, subcutaneous adipose tissue, and visceral adipose tissue were evaluated at the third lumbar spine vertebra on CT axial sections. Results: Median age of the 76 patients enrolled in this study was 75 years (59–91 years), and the median Gleason score was 8 (6–10). All patients received two to six (median 4) cycles of 7.4 GBq Lu-177 PSMA treatment at 6–8 week intervals. Upon univariant Cox regression analysis, subcutaneous adipose tissue index, right psoas myosteatosis, left psoas myosteatosis, and skeletal muscle index were determined to be prognostic factors for OS ( P = 0.03, P = 0.02, P < 0.001, and P = 0.04, respectively). However, the left psoas myosteatosis value was an independent prognostic factor for OS as determined by multivariant Cox regression analysis ( P < 0.001). Conclusion: Sarcopenia and myosteatosis before treatment were associated with shorter survival in mCRPC patients who were scheduled for Lu-177 PSMA treatment. Patients with left psoas myosteatosis value ≤26.85 HU had shorter OS, and we showed that OS is an independent prognostic factor.
- 1 May 2025
- Published by Wolters Kluwer Health in Nuclear Medicine Communications
- Vol. 46 (7) , 592-598
Effect of body composition parameters, including sarcopenia, myosteatosis, and adipose tissue, on overall survival of patients with mCRPC receiving 177Lu-PSMA PRRT
Purpose: This study aimed to examine the role of computed tomography (CT)-derived myosteatosis, sarcopenia, and other body composition parameters on overall survival (OS) in patients with metastatic castration-resistant prostate cancer (mCRPC) scheduled to receive lutetium (Lu)-177 treatment. Material and method: Patients with mCRPC who underwent 68 Ga-prostate-specific membrane antigen (PSMA) PET/CT imaging before [ 177 Lu]Lu-PSMA-617 treatment and received at least two cycles of Lu-177 PSMA treatment between March 2017 and March 2023 were retrospectively reviewed in this study. Body composition including psoas muscle, skeletal muscle, subcutaneous adipose tissue, and visceral adipose tissue were evaluated at the third lumbar spine vertebra on CT axial sections. Results: Median age of the 76 patients enrolled in this study was 75 years (59–91 years), and the median Gleason score was 8 (6–10). All patients received two to six (median 4) cycles of 7.4 GBq Lu-177 PSMA treatment at 6–8 week intervals. Upon univariant Cox regression analysis, subcutaneous adipose tissue index, right psoas myosteatosis, left psoas myosteatosis, and skeletal muscle index were determined to be prognostic factors for OS ( P = 0.03, P = 0.02, P < 0.001, and P = 0.04, respectively). However, the left psoas myosteatosis value was an independent prognostic factor for OS as determined by multivariant Cox regression analysis ( P < 0.001). Conclusion: Sarcopenia and myosteatosis before treatment were associated with shorter survival in mCRPC patients who were scheduled for Lu-177 PSMA treatment. Patients with left psoas myosteatosis value ≤26.85 HU had shorter OS, and we showed that OS is an independent prognostic factor.
- Open Access
- 20 February 2025
- Published by Springer Nature in BMC Gastroenterology
- Vol. 25 (1) , 1-6
Predictive value of the FIB-4 index, APRI, ALBI score, and GPR for overall survival in treatment-naïve metastatic colorectal cancer patients
The prevalence of metastatic colorectal cancer (mCRC) is increasing and is linked to poor overall survival (OS). Previous studies have aimed to determine the predictive value of scores and laboratory tests for OS in mCRC patients, but their findings have been inconclusive. In this research, we focused on determining the prognostic significance of the fibrosis-4 (FIB-4) index, the aspartate aminotransferase (AST) to platelet (PLT) ratio index (APRI), the albumin–bilirubin (ALBI) score, and the gamma-glutamyl transpeptidase to PLT ratio (GPR) with respect to OS in treatment-naïve mCRC patients. This retrospective study included treatment-naïve mCRC patients. The FIB-4 index, ALBI score, APRI, and GPR were calculated for each participant, and their mortality dates were recorded. The clinical importance of these scores for survival outcomes was evaluated via the Cox regression model, Kaplan–Meier method, and log-rank test. The study enrolled 123 untreated mCRC patients. Univariate Cox regression analysis demonstrated that sex and AST/PLT and ALT/PLT counts were not associated with OS (p > 0.05 for all). However, a higher FIB-4 index (p = 0.025), ALBI score (p < 0.001), GPR (p < 0.001), and AST/ALT ratio (p < 0.001) were all associated with poor OS. Additionally, multivariate Cox regression analysis indicated that age (95% CI: 1.009–1.053, p = 0.006), ALBI score (95% CI: 1.234–2.983, p = 0.004), GPR (95% CI: 1.442–2.701, p < 0.001), and AST/ALT (95% CI: 1.193–2.911, p = 0.006) were independent prognostic factors for OS. The affordable and easily accessible ALBI score, GPR, and AST/ ALT have prognostic value in untreated patients with mCRC.
- 20 February 2025
- Published by Springer Nature in BMC Gastroenterology
- Vol. 25 (1) , 1-6
Open AccessPredictive value of the FIB-4 index, APRI, ALBI score, and GPR for overall survival in treatment-naïve metastatic colorectal cancer patients
The prevalence of metastatic colorectal cancer (mCRC) is increasing and is linked to poor overall survival (OS). Previous studies have aimed to determine the predictive value of scores and laboratory tests for OS in mCRC patients, but their findings have been inconclusive. In this research, we focused on determining the prognostic significance of the fibrosis-4 (FIB-4) index, the aspartate aminotransferase (AST) to platelet (PLT) ratio index (APRI), the albumin–bilirubin (ALBI) score, and the gamma-glutamyl transpeptidase to PLT ratio (GPR) with respect to OS in treatment-naïve mCRC patients. This retrospective study included treatment-naïve mCRC patients. The FIB-4 index, ALBI score, APRI, and GPR were calculated for each participant, and their mortality dates were recorded. The clinical importance of these scores for survival outcomes was evaluated via the Cox regression model, Kaplan–Meier method, and log-rank test. The study enrolled 123 untreated mCRC patients. Univariate Cox regression analysis demonstrated that sex and AST/PLT and ALT/PLT counts were not associated with OS (p > 0.05 for all). However, a higher FIB-4 index (p = 0.025), ALBI score (p < 0.001), GPR (p < 0.001), and AST/ALT ratio (p < 0.001) were all associated with poor OS. Additionally, multivariate Cox regression analysis indicated that age (95% CI: 1.009–1.053, p = 0.006), ALBI score (95% CI: 1.234–2.983, p = 0.004), GPR (95% CI: 1.442–2.701, p < 0.001), and AST/ALT (95% CI: 1.193–2.911, p = 0.006) were independent prognostic factors for OS. The affordable and easily accessible ALBI score, GPR, and AST/ ALT have prognostic value in untreated patients with mCRC.
- 27 January 2025
- Published by Academician Publishing
- p. 1-8
Peptit Reseptör Radyonüklid Tedavi
- Open Access
- 27 January 2025
- Published by Academician Publishing
Güncel Radyoloji Çalışmaları IV
Peptit Reseptör Radyonüklid Tedavi İhsan KAPLAN Çocuklarda Konik Işınlı Bilgisayarlı Tomografi Kullanım Endikasyonları Sema KAYA Burçin AVCI Radyodirençlilikte GSTP-1 İzoenziminin Olası Rolü: Radyoterapiyle İndüklenen Ros Artışına Yanıt Murat KILIÇ İsmail Faruk DURMUŞ İleri Evre Hepatosellüler Karsinom Tedavisinde Transarteryel Radyoembolizasyon Sonrası Bilgisayarlı Tomografi Perfüzyon Görüntüleme Parametreleri Değişimi Ela KAPLAN Fatih ERBAY Ayşegül SAĞIR KAHRAMAN Müge OTLU KARADAĞ Ersoy KEKİLLİ Ramazan KUTLU Covid-19 Kardiyak Tutulumunda Manyetik Rezonans Görüntüleme Safa ÖZYILMAZ Temporomandibular Eklem Anatomisi ve Görüntüleme Yöntemleri Menduh Sercan KAYA Mehmet Emin DOĞAN Pediatrik Hastalarda Diz Görüntüleme Eren ÇAMUR
- 27 January 2025
- Published by Academician Publishing
Open AccessGüncel Radyoloji Çalışmaları IV
Peptit Reseptör Radyonüklid Tedavi İhsan KAPLAN Çocuklarda Konik Işınlı Bilgisayarlı Tomografi Kullanım Endikasyonları Sema KAYA Burçin AVCI Radyodirençlilikte GSTP-1 İzoenziminin Olası Rolü: Radyoterapiyle İndüklenen Ros Artışına Yanıt Murat KILIÇ İsmail Faruk DURMUŞ İleri Evre Hepatosellüler Karsinom Tedavisinde Transarteryel Radyoembolizasyon Sonrası Bilgisayarlı Tomografi Perfüzyon Görüntüleme Parametreleri Değişimi Ela KAPLAN Fatih ERBAY Ayşegül SAĞIR KAHRAMAN Müge OTLU KARADAĞ Ersoy KEKİLLİ Ramazan KUTLU Covid-19 Kardiyak Tutulumunda Manyetik Rezonans Görüntüleme Safa ÖZYILMAZ Temporomandibular Eklem Anatomisi ve Görüntüleme Yöntemleri Menduh Sercan KAYA Mehmet Emin DOĞAN Pediatrik Hastalarda Diz Görüntüleme Eren ÇAMUR
- 16 June 2024
- Published by Springer Nature in Annals of Nuclear Medicine
- Vol. 38 (10) , 825-834
Should new organ involvement be included in Response Evaluation Criteria in PSMA Imaging?
Purpose The current study is intended to investigate the effect of new organ involvement on overall survival (OS) and modify the Response Evaluation Criteria in PSMA Imaging (RECIP) by including new organ involvement to RECIP 1.0. Materials and methods This retrospective study includes 114 patients diagnosed with metastatic castration-resistant prostate cancer (mCRPC) between September 2017 and June 2022 who had received docetaxel treatment and had baseline and post-treatment prostate-specific membrane antigen (PSMA) positron emission tomography/computed tomography (PET/CT) images. The inclusion criteria were patients with pre- and post-treatment [18F]FDG PET/CT images and whose [18F]FDG PET images were negative. Those whose data were unavailable, who had additional malignancy, or who received abiraterone, enzalutamide, or Lutetium (Lu)-177 treatment were excluded. Age, Gleason score (GS), TPSA (total prostate-specific antigen) levels, surgical history, and OS information were recorded for each patient. Results The 114 patients herein had a median age of 72.5 (51–91) years and a median GS of 8 (7–10). New lesions were observed in 59 patients (51.7%) and new organ PSMA uptake was observed in 14 patients (12.2%). In the multivariate Cox regression analysis, volume-based treatment response (vTR)-total lesion PSMA (TLP), RECIP PSMA-VOL, modified RECIP (mRECIP) PSMA-VOL, and mRECIP TLP were independent prognostic factors for mortality (p < 0.001, p = 0.006, p = 0.003, and p = 0.003, respectively). The median OS of patients with new organ involvement and new lesion with PSMA uptake was 9.3 months (95% CI 2.1–16.5 months) and 11.8 months (95% CI 7.4–16.2 months), respectively. Conclusion The study concluded that new organ involvement had a shorter OS than new lesion involvement. In the mRECIP that we developed, unlike RECIP, we demonstrated that both PSMA-VOL and TLP value were independent prognostic factors for mortality.
- 16 June 2024
- Published by Springer Nature in Annals of Nuclear Medicine
- Vol. 38 (10) , 825-834
Should new organ involvement be included in Response Evaluation Criteria in PSMA Imaging?
Purpose The current study is intended to investigate the effect of new organ involvement on overall survival (OS) and modify the Response Evaluation Criteria in PSMA Imaging (RECIP) by including new organ involvement to RECIP 1.0. Materials and methods This retrospective study includes 114 patients diagnosed with metastatic castration-resistant prostate cancer (mCRPC) between September 2017 and June 2022 who had received docetaxel treatment and had baseline and post-treatment prostate-specific membrane antigen (PSMA) positron emission tomography/computed tomography (PET/CT) images. The inclusion criteria were patients with pre- and post-treatment [18F]FDG PET/CT images and whose [18F]FDG PET images were negative. Those whose data were unavailable, who had additional malignancy, or who received abiraterone, enzalutamide, or Lutetium (Lu)-177 treatment were excluded. Age, Gleason score (GS), TPSA (total prostate-specific antigen) levels, surgical history, and OS information were recorded for each patient. Results The 114 patients herein had a median age of 72.5 (51–91) years and a median GS of 8 (7–10). New lesions were observed in 59 patients (51.7%) and new organ PSMA uptake was observed in 14 patients (12.2%). In the multivariate Cox regression analysis, volume-based treatment response (vTR)-total lesion PSMA (TLP), RECIP PSMA-VOL, modified RECIP (mRECIP) PSMA-VOL, and mRECIP TLP were independent prognostic factors for mortality (p < 0.001, p = 0.006, p = 0.003, and p = 0.003, respectively). The median OS of patients with new organ involvement and new lesion with PSMA uptake was 9.3 months (95% CI 2.1–16.5 months) and 11.8 months (95% CI 7.4–16.2 months), respectively. Conclusion The study concluded that new organ involvement had a shorter OS than new lesion involvement. In the mRECIP that we developed, unlike RECIP, we demonstrated that both PSMA-VOL and TLP value were independent prognostic factors for mortality.
- 8 June 2024
- Published by Wolters Kluwer Health in Clinical Nuclear Medicine
- Vol. 49 (9) , e464-e467
68Ga-PSMA Versus 18F-FDG PET/CT in the Evaluation of Epithelioid Hemangioendothelioma
A 32-year-old man with epithelioid hemangioendothelioma was imaged with 68Ga-PSMA PET/CT to evaluate the potential of 177Lu-PSMA radionuclide therapy after progression findings were observed on follow-up 18F-FDG PET/CT imaging. Liver lesions showed low FDG SUVmax. The lesion-to-background ratio (TBR) was calculated as 5.1/2.9 on 18F-FDG PET/CT imaging. However, 68Ga-PSMA PET/CT showed moderate PSMA SUVmax. TBR was calculated as 4.5/1.1. In conclusion, in this case report, we demonstrated that 68Ga-PSMA with moderate TBR in epithelioid hemangioendothelioma may be promising for 177Lu-PSMA radionuclide therapy.
- 8 June 2024
- Published by Wolters Kluwer Health in Clinical Nuclear Medicine
- Vol. 49 (9) , e464-e467
68Ga-PSMA Versus 18F-FDG PET/CT in the Evaluation of Epithelioid Hemangioendothelioma
A 32-year-old man with epithelioid hemangioendothelioma was imaged with 68Ga-PSMA PET/CT to evaluate the potential of 177Lu-PSMA radionuclide therapy after progression findings were observed on follow-up 18F-FDG PET/CT imaging. Liver lesions showed low FDG SUVmax. The lesion-to-background ratio (TBR) was calculated as 5.1/2.9 on 18F-FDG PET/CT imaging. However, 68Ga-PSMA PET/CT showed moderate PSMA SUVmax. TBR was calculated as 4.5/1.1. In conclusion, in this case report, we demonstrated that 68Ga-PSMA with moderate TBR in epithelioid hemangioendothelioma may be promising for 177Lu-PSMA radionuclide therapy.